1. Home
  2. AMCX vs DCTH Comparison

AMCX vs DCTH Comparison

Compare AMCX & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo AMC Networks Inc.

AMCX

AMC Networks Inc.

N/A

Current Price

$10.83

Market Cap

492.0M

ML Signal

N/A

DCTH

Delcath Systems Inc.

N/A

Current Price

$15.26

Market Cap

578.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
AMCX
DCTH
Founded
1980
1988
Country
United States
United States
Employees
N/A
N/A
Industry
Cable & Other Pay Television Services
Medical/Dental Instruments
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
492.0M
578.4M
IPO Year
2011
2015

Fundamental Metrics

Financial Performance
Metric
AMCX
DCTH
Price
$10.83
$15.26
Analyst Decision
Sell
Strong Buy
Analyst Count
8
5
Target Price
$9.83
★ $24.00
AVG Volume (30 Days)
★ 558.5K
306.8K
Earning Date
11-06-2026
11-03-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 132.55
107.53
EPS
N/A
★ 0.04
Revenue
★ $2,311,801,000.00
N/A
Revenue This Year
$5.07
$24.61
Revenue Next Year
N/A
$24.27
P/E Ratio
★ N/A
$376.00
Revenue Growth
N/A
★ N/A
52 Week Low
$6.47
$8.12
52 Week High
$12.93
$17.42

Technical Indicators

Market Signals
Indicator
AMCX
DCTH
Relative Strength Index (RSI) 36.47 43.91
Support Level $9.13 $9.98
Resistance Level $11.13 $16.51
Average True Range (ATR) 0.36 0.53
MACD -0.12 -0.11
Stochastic Oscillator 10.99 39.01

Price Performance

Historical Comparison
AMCX
DCTH

About AMCX AMC Networks Inc.

AMC Global Media owns several linear TV networks, including AMC, WE tv, BBC America, IFC, and SundanceTV. AMC, its most widely distributed network,reached 55 million pay TV households in the US at the end of 2025. The firm also had nearly 10.5 million US streaming subscribers, with AMC+ as the flagship streaming platform. With both its linear networks and streaming offerings, the firm caters to specific niche audiences. Over the last 15 years, AMC has shifted its focus to original scripted programming from classic movies. It creates content through AMC Studios and also generates revenue from licensing content. Following an international divestiture at the end of 2023, domestic operations make up nearly 90% of total revenue.

About DCTH Delcath Systems Inc.

Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.

Share on Social Networks: